4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9 daahirnimo>98.5% (HPLC) Lenvatinib Mesylate Warshada Dhexe
Qalabka Kiimikada ee Ruifu Lenvatinib Mesylate Dhexdhexaadiyeyaasha oo leh nadiif sare
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene) -2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Magaca Kiimikada | 4-Chloro-7-Methoxyquinoline-6-Carboxamide |
La mid ah | 4-Chloro-7-Methoxy-6-Quinolinecarboxamide;Lenvatinib wasakhnimada 12;Lenvatinib wasakh B;Lenvatinib wasakh LFS-B |
Lambarka CAS | 417721-36-9 |
Lambarka CAT | RF-PI1971 |
Heerka Saamiyada | Kaydka dhexdiisa, Awoodda Wax-soo-saarka 50MT/Sannadka |
Qaanuunka molecular | C11H9ClN2O2 |
Miisaanka Molecular | 236.65 |
Meesha dhalaalaysa | >205 ℃ (dac.) |
Cufnaanta | 1.380± 0.060 g/cm3 |
Summada | Kiimikada Ruifu |
Shayga | Tilmaamaha |
Muuqashada | Ka-bax-caddan ilaa budada jaalaha ah ee khafiifka ah |
Daahirnimada / Habka Falanqaynta | > 98.5% (HPLC) |
Khasaare xagga qalajinta | <0.50% |
Hadhaaga dabka | <0.50% |
Wadarta wasakhda | <1.50% |
Proton NMR Spectrum | Waafaqsan Qaab-dhismeedka |
Heerka Imtixaanka | Heerka Ganacsiga |
Isticmaalka | Dhexdhexaadiyaha Lenvatinib Mesylate (CAS: 857890-39-2) |
Xidhmada: Dhalo, bacda bireed aluminium, 25kg / Durbaan kartoonada, ama sida waafaqsan shuruudaha macmiilka
Xaaladda Kaydinta:Ku kaydi weelasha xiran meel qabow oo qallalan;Ka ilaali iftiinka iyo qoyaanka
4-Chloro-7-Methoxyquinoline-6-Carboxamide (CAS: 417721-36-9) waxaa inta badan loo isticmaalaa sidii dhexe ee Lenvatinib Mesylate (CAS: 857890-39-2).Waxaa sameeyay Eisai Inc., lenvatinib mesylate waa vascular endothelial factor factor reseptor (VEGF) inhibitor kaas oo leh waxqabad ka dhan ah VEGF subtypes 1, 2, iyo 3 waxaana ansixiyay FDA 2015 si loogu daaweeyo kansarka qanjirka thyroid ee kala duwan soo noqnoqda, metastatic, ama horusocod ah oo aan ka jawaabin daaweynta iodine radioactive.Bishii Maajo 2016, FDA waxay oggolaatay daawada sida isku-darka daaweynta weligeed ah ee daaweynta kansarka unugyada kelyaha ee horumarsan.Sababtoo ah VEGF (iyo fibroblast factor factor reseptors, oo loo yaqaan FGFRs) ayaa loo maleynayaa inay door ka ciyaaraan waddooyinka calaamadaha wadnaha, VEGF2R iyo FGFR waxay u maleynayaan inay yihiin hababka ka dambeeya saameynta asaasiga ah ee lenvatinib mesylate, taas oo ah hypertension.